BioSpectrum the business of Bio & Health Sciences ASIA EDITION

QPS CRO opens office in China

03 October 2012 | News | By BioSpectrum Bureau

QPS CRO opens office in China

Singapore: QPS Holdings, a leading full-service clinical research organization, announced the launch of its QPS Qualitix China Office, built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China. QPS already has a presence in Taiwan and India.

Capitalizing on its experience conducting clinical trials through partners in China, the QPS Qualitix China Office will focus on developing customized solutions to help local and global biopharma companies achieve successful registration of new medicines in China. The expansion into China continues QPS' development of its worldwide capabilities and focus on emerging markets.

The QPS Qualitix China Office will provide a full range of knowledge-based contract research services, including comprehensive clinical trial management and regulatory submission preparation. The new China Office will tap QPS' global resources and expertise to develop customized offerings in key therapeutic areas, along with phase II-IV studies, biostatistics, data management, medical writing, vaccines, medical devices and diagnostics.

"The QPS Qualitix China Office will leverage QPS' quality and training systems to offer customized, high-quality drug development solutions best suited for local Chinese biopharma, as well as global biopharma's local affiliates," says Mr Vincent Yen, general manager, QPS Qualitix China. "We have an aggressive growth plan for China and anticipate increasing QPS' total staff there during 2012 as we look to provide our customers with the solutions they need to succeed in one of the world's most dynamic marketplaces."

The new QPS Qualitix China Office is located in the Chao Yang district, near the World Trade Center of Beijing. The office will be headed by David Hsu, who brings years of experience in the clinical research industry, with both global pharmaceutical companies and CROs.